GSK makes a $124-a-share run at Nuvalent

GSK just went shopping

GSK’s indirect subsidiary, Harmony Row Acquisition Co., has officially started a tender offer to scoop up all outstanding Nuvalent shares for $124 in cash apiece. In other words: this isn’t a rumor mill whisper or a “sources say” dance — it’s the real M&A paperwork starting to move.

Why investors should care

For Nuvalent shareholders, the headline is the cash price. That kind of bid gives the stock a hard ceiling and turns the story from “what could this biotech become?” into “will the deal close smoothly?” For GSK, it’s a sign the company is still willing to buy growth instead of waiting around for it to magically appear in a lab flask.

The fine print that matters

• GSK is buying through a subsidiary, which is a pretty standard way to handle these deals.
• The offer is for all outstanding Nuvalent shares.
• The deal value per share is clear; the full equity value wasn’t included in the snippet, so we’re not pretending otherwise.

Big picture: biotech M&A tends to wake up when big pharma wants pipeline, not patience. Today GSK is paying for both.